Dosing Begins in Study of TP-0903, With or Without Imbruvica, for Advanced CLL and SLL
News
Dosing with the investigational therapy TP-0903 has begun in patients with previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in an ongoing Phase 1/2 trial, its developer, Tolero Pharmaceuticals, announced. ... Read more